HUTCHMED (China) Limited (H7T1) - Total Liabilities
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has total liabilities worth €534.02 Million EUR (≈ $624.32 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore HUTCHMED (China) Limited (H7T1) cash conversion ratio to assess how effectively this company generates cash.
HUTCHMED (China) Limited - Total Liabilities Trend (2016–2024)
This chart illustrates how HUTCHMED (China) Limited's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are HUTCHMED (China) Limited's assets to evaluate the company's liquid asset resilience ratio.
HUTCHMED (China) Limited Competitors by Total Liabilities
The table below lists competitors of HUTCHMED (China) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huada Automotive Tech Corp Ltd
SHG:603358
|
China | CN¥3.29 Billion |
|
Longshine Technology Co Ltd
SHE:300682
|
China | CN¥2.29 Billion |
|
Ströer SE & Co. KGaA
F:SAX
|
Germany | €2.39 Billion |
|
Beijing Zhong Ke San Huan High-Tech Co Ltd
SHE:000970
|
China | CN¥3.09 Billion |
|
Sichuan Anning Iron and Titanium Co
SHE:002978
|
China | CN¥8.09 Billion |
|
Roshow Technology Co Ltd
SHE:002617
|
China | CN¥4.22 Billion |
|
Triumph Science & Technology Co Ltd
SHG:600552
|
China | CN¥7.32 Billion |
|
Mtar Technologies Limited
NSE:MTARTECH
|
India | Rs4.30 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down HUTCHMED (China) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HUTCHMED (China) Limited (H7T1) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED (China) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED (China) Limited (2016–2024)
The table below shows the annual total liabilities of HUTCHMED (China) Limited from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €502.34 Million ≈ $587.29 Million |
-6.35% |
| 2023-12-31 | €536.39 Million ≈ $627.09 Million |
+36.63% |
| 2022-12-31 | €392.57 Million ≈ $458.96 Million |
+17.84% |
| 2021-12-31 | €333.15 Million ≈ $389.48 Million |
+62.38% |
| 2020-12-31 | €205.17 Million ≈ $239.86 Million |
+34.79% |
| 2019-12-31 | €152.22 Million ≈ $177.96 Million |
+26.99% |
| 2018-12-31 | €119.86 Million ≈ $140.13 Million |
+6.11% |
| 2017-12-31 | €112.97 Million ≈ $132.07 Million |
-18.36% |
| 2016-12-31 | €138.38 Million ≈ $161.78 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more